Tags

Type your tag names separated by a space and hit enter

Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy.
J Infect Dis. 2004 Apr 15; 189(8):1444-51.JI

Abstract

The mechanisms involved in maintaining a latent replication-competent integrated human immunodeficiency virus type 1 (HIV-1) reservoir after successful highly active antiretroviral therapy (HAART) have not been fully described. The objective of this study was to assess whether low-level, persistent HIV-1 replication can be detected in the protease gene, in 10 HIV-1-infected patients who have undergone 2 years of successful HAART. Peripheral blood mononuclear cells (PBMCs) were collected from 10 HIV-1-infected patients receiving a triple-drug combination therapy (2 nucleoside analogues and 1 protease inhibitor). HIV-1 RNA levels and CD4+ and CD8+ T cell counts were longitudinally determined during a follow-up period of 108 weeks. Similarly, proviral fragments of the protease-coding region, obtained at baseline and at week 108 of HAART, were amplified by polymerase chain reaction from PBMCs, and 10-25 individual clones were sequenced for each time point. Only 1 of 271 individual protease clones showed a major resistance substitution (M46I [patient D]). Phylogenetic analysis revealed that, in all patients, the genetic distances from the deduced most recent common ancestor, in samples obtained at week 108 of HAART, were not longer than those in samples obtained at baseline. Moreover, the pattern of amino acid divergence during therapy showed an absence of positive selection in the protease-coding region. Taken together, these results show a lack of clinically relevant evolution in the protease-coding region after 2 years of successful HAART.

Authors+Show Affiliations

Fundacio irsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona, and Universitat Autonoma de Barcelona, Barcelona, Spain.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15073682

Citation

Parera, Mariona, et al. "Lack of Evidence for Protease Evolution in HIV-1-infected Patients After 2 Years of Successful Highly Active Antiretroviral Therapy." The Journal of Infectious Diseases, vol. 189, no. 8, 2004, pp. 1444-51.
Parera M, Ibañez A, Clotet B, et al. Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy. J Infect Dis. 2004;189(8):1444-51.
Parera, M., Ibañez, A., Clotet, B., & Martinez, M. A. (2004). Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy. The Journal of Infectious Diseases, 189(8), 1444-51.
Parera M, et al. Lack of Evidence for Protease Evolution in HIV-1-infected Patients After 2 Years of Successful Highly Active Antiretroviral Therapy. J Infect Dis. 2004 Apr 15;189(8):1444-51. PubMed PMID: 15073682.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy. AU - Parera,Mariona, AU - Ibañez,Angela, AU - Clotet,Bonaventura, AU - Martinez,Miguel Angel, Y1 - 2004/04/05/ PY - 2003/07/25/received PY - 2003/09/24/accepted PY - 2004/4/10/pubmed PY - 2004/5/27/medline PY - 2004/4/10/entrez SP - 1444 EP - 51 JF - The Journal of infectious diseases JO - J Infect Dis VL - 189 IS - 8 N2 - The mechanisms involved in maintaining a latent replication-competent integrated human immunodeficiency virus type 1 (HIV-1) reservoir after successful highly active antiretroviral therapy (HAART) have not been fully described. The objective of this study was to assess whether low-level, persistent HIV-1 replication can be detected in the protease gene, in 10 HIV-1-infected patients who have undergone 2 years of successful HAART. Peripheral blood mononuclear cells (PBMCs) were collected from 10 HIV-1-infected patients receiving a triple-drug combination therapy (2 nucleoside analogues and 1 protease inhibitor). HIV-1 RNA levels and CD4+ and CD8+ T cell counts were longitudinally determined during a follow-up period of 108 weeks. Similarly, proviral fragments of the protease-coding region, obtained at baseline and at week 108 of HAART, were amplified by polymerase chain reaction from PBMCs, and 10-25 individual clones were sequenced for each time point. Only 1 of 271 individual protease clones showed a major resistance substitution (M46I [patient D]). Phylogenetic analysis revealed that, in all patients, the genetic distances from the deduced most recent common ancestor, in samples obtained at week 108 of HAART, were not longer than those in samples obtained at baseline. Moreover, the pattern of amino acid divergence during therapy showed an absence of positive selection in the protease-coding region. Taken together, these results show a lack of clinically relevant evolution in the protease-coding region after 2 years of successful HAART. SN - 0022-1899 UR - https://www.unboundmedicine.com/medline/citation/15073682/Lack_of_evidence_for_protease_evolution_in_HIV_1_infected_patients_after_2_years_of_successful_highly_active_antiretroviral_therapy_ L2 - https://academic.oup.com/jid/article-lookup/doi/10.1086/382485 DB - PRIME DP - Unbound Medicine ER -